MARKET

DXCM

DXCM

Dexcom Inc
NASDAQ
68.30
-1.68
-2.40%
Opening 11:53 06/30 EDT
OPEN
70.96
PREV CLOSE
69.98
HIGH
70.96
LOW
68.10
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
89.98
52 WEEK LOW
54.11
MARKET CAP
26.36B
P/E (TTM)
29.46
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DXCM last week (0622-0626)?
Weekly Report · 1d ago
Is DexCom (DXCM) A Bargain On FDA Cleared Stelo Expansion?
Simply Wall St · 1d ago
Notable healthcare headlines for the week: Merck, AbbVie, and Bayer in focus
Seeking Alpha · 2d ago
DexCom (DXCM) Launches New Stelo App As It Expands Into Four Countries
Simply Wall St · 3d ago
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
NASDAQ · 4d ago
DexCom announces milestones to make glucose biosensing more accessible
TipRanks · 06/23 16:10
DexCom, Insulet gain news Buys at Deutsche Bank despite recent selloff
Seeking Alpha · 06/23 15:23
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 06/23 13:47
More
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.

Webull offers DexCom Inc stock information, including NASDAQ: DXCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DXCM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DXCM stock methods without spending real money on the virtual paper trading platform.